{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:04:19Z","timestamp":1784610259028,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Functional imaging is central to the diagnosis and management of phaeochromocytomas and paragangliomas (PPGLs). This study aimed to compare the diagnostic performance of different functional imaging modalities for the detection of primary and metastatic PPGL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective, cross-sectional comparative study at a tertiary referral centre (2012\u20132023). Seventy three patients were with diagnosed with PPGL; 38 who underwent triple functional imaging. These 38 patients underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET CT\/MRI (FDG), and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTATATE PET\/CT (Dotatate), and\n                      <jats:sup>123<\/jats:sup>\n                      I-mIBG SPECT\/CT (mIBG). Per-patient detection rates for primary and metastatic disease were compared and correlated with SUV\n                      <jats:sub>max<\/jats:sub>\n                      , metanephrine profiles and germline mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 38 patients who underwent triple functional imaging, 18 (47%) were women, with a median age of 41 years (range 11-81). There were 23 phaeochromocytomas and 15 paragangliomas. Overall detection rates were positive in 36\/38 (94.7%) patients on FDG, 35\/38 (92.1%) on Dotatate, and 34\/38 (89.5%) on mIBG. Among patients with metastatic disease, lesion detection was observed in 16\/16 (100%) with FDG, 12\/13 (92.3%) with Dotatate, and 11\/13 (84.6%) with mIBG. FDG SUV\n                      <jats:sub>max<\/jats:sub>\n                      correlated significantly with plasma 3-methoxytyramine levels (r = 0.56, p = 0.0034) but not with normetanephrine or metanephrine. FDG demonstrated 100% detection in patients with SDHB (6\/6) and VHL (3\/3) mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, FDG demonstrated the highest per-patient detection and the strongest association with aggressive biochemical and genetic phenotypes. These findings support an FDG-first functional imaging strategy for diagnosis and staging in PPGL, with additional targeted imaging reserved for theranostic decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1833759","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:20:19Z","timestamp":1784607619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["An FDG-first functional imaging approach in phaeochromocytoma and paraganglioma"],"prefix":"10.3389","volume":"17","author":[{"given":"Norah","family":"Alhazzaa","sequence":"first","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M. R.","family":"Eddama","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawziah","family":"Alorfi","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Teng","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srirangalingam","family":"Umasuthan","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Hurel","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rozalen-Garcia","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Kurzawinski","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gaze","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Ezzat","family":"Abdel-Aziz","sequence":"additional","affiliation":[{"name":"Department of Targeted Intervention, Division of Surgery and Interventional Science, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1021420","article-title":"Silent pheochromocytoma and paraganglioma: systematic review and proposed definitions for standardized terminology","volume":"13","author":"Constantinescu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1677\/erc-07-0217","article-title":"Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations","volume":"15","author":"Zelinka","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248021","article-title":"First experience using 18F-flubrobenguane PET imaging in patients with suspected pheochromocytoma or paraganglioma","volume":"62","author":"Kessler","year":"2021","journal-title":"J Nucl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-56968-5_25","article-title":"Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma","volume":"55","author":"van Berkel","year":"2014","journal-title":"J Nucl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4158\/ep15725.or","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocrine Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Hormone Metab Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07247-6","article-title":"Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children","volume":"52","author":"Peet","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24030","article-title":"Phaeochromocytomas and paragangliomas: a difference in disease behaviour and clinical outcomes","volume":"112","author":"Ezzat Abdel-Aziz","year":"2015","journal-title":"J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-200207000-00007","article-title":"Management of Malignant pheochromocytoma","volume":"12","author":"Yu","year":"2002","journal-title":"Endocrinologist"},{"key":"B13","article-title":"Pheochromocytoma and paraganglioma","volume-title":"Endotext","author":"Pacak","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Institute"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1075-3","article-title":"The new EANM paediatric dosage card","volume":"34","author":"Lassmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68 Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18 F\u2013DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2991\/978-2-38476-444-0_45","article-title":"Comparison of the 68Ga-DOTATATA PET\/CT, FDG PET\/CT, and MIBG SPECT\/CT in the evaluation of suspected primary pheochromocytomas and paragangliomas","volume":"42","author":"Jing","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216796","article-title":"Metabolic subtyping of pheochromocytoma and paraganglioma by 18F-FDG pharmacokinetics using dynamic PET\/CT scanning","volume":"60","author":"van Berkel","year":"2019","journal-title":"J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"68Ga-DOTATATE and 18F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.060731","article-title":"18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature","volume":"50","author":"Ta\u00efeb","year":"2009","journal-title":"J Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.140137","article-title":"Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation","volume":"55","author":"Sinusas","year":"2014","journal-title":"J Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03257.x","article-title":"The role of 18F-FDOPA and 18F-FDG\u2013PET in the management of Malignant and multifocal phaeochromocytomas","volume":"69","author":"Taieb","year":"2008","journal-title":"Clin Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0758-5","article-title":"FDG uptake, a surrogate of tumour hypoxia","volume":"35","author":"Dierckx","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1737","article-title":"Mitochondrial tumour suppressors: a genetic and biochemical update","volume":"5","author":"Gottlieb","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with Malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0045-1807251","article-title":"Global challenges in the provision of theranostic services the International Atomic Energy Agency (IAEA) perspective","volume":"24","author":"Brink","year":"2025","journal-title":"World J Nucl Med"},{"key":"B33","article-title":"Pheochromocytoma and paraganglioma treatment (PDQ\u00ae)","volume-title":"Pdq Cancer Information Summaries [Internet]","year":"2010"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-5-462","article-title":"Molecular radiotheranostics for neuroendocrine tumours","volume":"17","author":"Navalkissoor","year":"2017","journal-title":"Clin Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06064-5","article-title":"18F] mFBG PET\/CT imaging outperforms MRI and [68 Ga] Ga-DOTA-TOC PET\/CT in identifying recurrence pheochromocytoma","volume":"50","author":"Suurd","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000004664","article-title":"Comparison of 18F-FDOPA and 18F-MFBG PET\/CT images of metastatic pheochromocytoma","volume":"48","author":"Wei","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000534175","article-title":"Predictive factors of early 18F-fluorodeoxyglucose-positron emission tomography response to [131I] metaiodobenzylguanidine treatment for unresectable or metastatic pheochromocytomas and paragangliomas","volume":"114","author":"Takenaka","year":"2024","journal-title":"Neuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111305","article-title":"The biochemical-imaging connection: urinary noradrenaline and fluorodeoxyglucose-positron emission tomography in unresectable or metastatic pheochromocytomas and paragangliomas","volume":"15","author":"Takenaka","year":"2025","journal-title":"Diagnostics (Basel)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:20:20Z","timestamp":1784607620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1833759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1833759"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1833759","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1833759"}}